1. Home
  2. TVRD
  3. TVRD News

Latest Tvardi Therapeutics Inc. Common Stock (TVRD) News on November 4, 2025

Down 83.0% in 4 Weeks, Here's Why Tvardi (TVRD) Looks Ripe for a Turnaround
TVRD

Zacks

19 days ago

Down 83.0% in 4 Weeks, Here's Why Tvardi (TVRD) Looks Ripe for a Turnaround

TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
TVRD

Zacks

21 days ago

TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals

AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance
TVRD

BioPharma Dive

21 days ago

AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance

Why Tvardi Therapeutics (TVRD) Is Down 83.3% After Disappointing Phase 2 TTI-101 IPF Trial Results
TVRD

Simply Wall St.

22 days ago

Why Tvardi Therapeutics (TVRD) Is Down 83.3% After Disappointing Phase 2 TTI-101 IPF Trial Results

TVRD

MT Newswires

22 days ago

Top Midday Decliners

TVRD

MT Newswires

22 days ago

Barclays Initiates Tvardi Therapeutics at Overweight With $61 Price Target

TVRD

MT Newswires

22 days ago

Sector Update: Health Care Stocks Higher Premarket Monday

TVRD

MT Newswires

22 days ago

Tvardi Therapeutics' Potential Lung Disease Treatment Fails to Meet Goals; Shares Decline Pre-Bell

TVRD

Business Wire

22 days ago

Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) most popular amongst retail investors who own 57% of the shares, institutions hold 26%
TVRD

Simply Wall St.

24 days ago

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) most popular amongst retail investors who own 57% of the shares, institutions hold 26%

Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks
TVRD

TipRanks

5 months ago

Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks

TVRD

Business Wire

5 months ago

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

TVRD

Business Wire

5 months ago

Tvardi Therapeutics to Participate in Upcoming Investor Conferences

TVRD

Business Wire

6 months ago

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

TVRD

Business Wire

6 months ago

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference

Share on Social Networks: